#2 - Eli Lilly (NYSE:LLY)
Eli Lilly and Co. (NYSE: LLY) is the current leader among GLP-1 drug stocks. Although its 72% growth in the past 12 months lags behind Novo Nordisk, LLY stock is up 64.6% in 2024, nearly double that of NVO stock. In the first two quarters of Lilly’s FY2024, revenue is up 28%. That’s 48% higher than the growth in the same two quarters of FY2023. And GLP-1 drugs now account for approximately 40% of the company’s revenue.
The company was second to market with its GLP-1 drugs. However, recent clinical results have shown its Mounjaro (diabetes) and Zepbound (obesity) drugs to be more effective than Novo Nordisk's, which was first to market.
Lilly is not immune to the supply chain issues that are plaguing this sector. The company simply doesn’t have enough manufacturing capacity to meet the growing demand. At the same time, like Novo Nordisk, Eli Lilly is making efforts to expand into different markets.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More - Current Price
- $795.35
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 17 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $1,007.94 (26.7% Upside)
